Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

115P - Geriatric breast cancer- Does age matter?


04 May 2022


Poster Display session


Talluri Surya


Annals of Oncology (2022) 33 (suppl_3): S175-S183. 10.1016/annonc/annonc891


T.S.H.V. Surya1, S.V.S. Deo1, D.N. Sharma1, A. Gogiya1, S. Bhoriwal2, A. MISHRA1

Author affiliations

  • 1 AIIMS - All India Institute of Medical Sciences, New Delhi/IN
  • 2 AIIMS - All India Institute of Medical Sciences, 110029 - New Delhi/IN

Abstract 115P


The management of breast cancer in elderly patients poses a complex array of challenges due to comorbid illnesses, poor functional status, social issues. There is a paucity of breast cancer data in geriatric patients from developing countries.


We analyzed the prospectively maintained, computerized breast cancer patient database in the department of surgical oncology. We included the breast cancer patients treated from January 1994 to December 2019. We considered the age at diagnosis of greater than or equal to 65 years to define Geriatric breast cancer (GBC) and analyzed the demography, clinical presentation, stage, histology, molecular subtypes, treatment details, survival outcomes and relapse patterns in these patients.


We identified 4628 breast cancer patients treated during the study period. Of them, 499 ( 10.78%) were Geriatric breast cancer patients. The mean age in this subset was 70.10 years, and 96.99% of patients were females. 330 patients (66.13 %) were between 65 to 70 years, and 3.0% were above 80 years. 49.8 % presented with early breast cancer and 4.6% had stage IV disease. Infiltrative ductal carcinoma was the most common histological subtype (88.7%). 41.4% of patients had luminal-A molecular subtype and 20% were triple-negative. The majority (84.0%) of patients underwent surgery first, mostly mastectomy and the breast conservation rate was 8.6%. The chemotherapy utilization rate was 28.2%, while 32.4% of patients received adjuvant radiotherapy. All luminal subtype patients received adjuvant hormonal therapy. Overall relapse rate was 16.2% (loco-regional relapse-6.2%; systemic relapse -10%). The most common site of systemic recurrence was bone, followed by lung, liver and brain. The 5-year overall survival (OS) and 5-year disease-free survival was 79.8% and 70.8%, respectively.


Geriatric breast cancer comprised 10.7 % of all breast cancers in the current study. Most patients presented between 65-70 years and mainly underwent an upfront mastectomy. With meticulous management in a multi-disciplinary setting, a 5-year OS of 79.8% can be achieved.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.